Clinical Trial Update: DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating CDX-1401, Poly ICLC, and INCB024360 in remission for ovarian, fallopian tube, or primary peritoneal cancer completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Ovarian Carcinoma
• Peritoneal Carcinoma

Drugs mentioned

• CDX-1401 (DEC-205/NY-ESO-1 fusion protein) (DEC-205/NY-ESO-1 fusion protein)
• INCB024360 (epacadostat)
• Poly IC:LC (polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose (poly-ICLC))

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Fallopian Tube Carcinoma, Ovarian Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-02-24